Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment

14 Jun 2022

Abstract excerpt

Replication-deficient adenoviral vectors have been under investigation as a platform technology for vaccine development for several years and have recently been successfully deployed as an effective COVID-19 counter measure. A replication-deficient adenoviral vector based on the simian adenovirus type Y25 and named ChAdOx1 has been evaluated in several clinical trials since 2012. The Brighton Collaboration...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to SARS-CoV-2 and COVID-19 Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35715352
DOI: 10.1016/j.vaccine.2022.06.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessmentPMID 35715352Read ↗

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessmentSemantic proximity Read ↗

Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive ReviewSemantic proximity Read ↗

The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 VaccineSemantic proximity Read ↗

Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral VectorsSemantic proximity Read ↗

Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2Semantic proximity Read ↗

The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platformSemantic proximity Read ↗

Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster modelSemantic proximity Read ↗

Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and SafetySemantic proximity Read ↗

Translational Virology - COVID-19, The Perfect ExampleSemantic proximity Read ↗

New Insights on Adenovirus as Vaccine VectorsSemantic proximity Read ↗

Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A AntigensSemantic proximity Read ↗

The Structure of ChAdOx1/AZD-1222 Reveals Interactions with CAR and PF4 with Implications for Vaccine-induced Immune Thrombotic ThrombocytopeniaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.